BayesPharma can support different customers at different points in development while keeping evidence, model provenance, uncertainty and accountable human decisions inspectable.
Build an inspectable bridge from development-candidate evidence into early clinical planning without upgrading predictions into experimental facts.
Deliverables: FIH evidence package, MRSD/MABEL/PAD scenarios, exposure margins, uncertainty/risk register, SAD/MAD planning inputs, multidisciplinary review packet.Model human PK, characterize variability and optimize the studies needed to learn efficiently.
Deliverables: PopPK workspace/model versions, sparse-sampling strategy, exposure simulations, special-population scenarios, model diagnostics, clinical pharmacology reports.Connect measured efficacy/safety with exposure-response and trial operating characteristics to support a governed dose-selection decision.
Deliverables: exposure-response package, active-dose set, uncertainty/evidence gaps, dose-ranging simulations, adaptive/futility scenarios, human dose-selection review packet.Stress-test design assumptions before protocol/SAP decisions become expensive.
Deliverables: sample-size/power scenarios, group-sequential operating characteristics, endpoint/estimand review, protocol precedent, competitive evidence, model credibility packet.Turn model runs and clinical evidence into a reproducible, reviewable chain rather than a folder of disconnected outputs.
Deliverables: context-of-use record, model risk/impact rationale, verification/validation evidence, audit history, decision traceability and reviewer-response support.Carry real-world datasets from harmonization through confounding diagnostics and treatment/safety evidence with an audit trail.
Deliverables: curated study dataset, causal-analysis evidence chain, safety/effectiveness analyses, evidence-grade and bias-risk record.None of these offerings replace qualified clinicians, toxicologists, statisticians, regulatory professionals, ethics review, CRO/site execution or regulator-issued decisions.
Programme context stays with you across Innovator · Evidence classes remain explicit · Heavy workflows require confirmation · Do not share identifiable patient data.